http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102965429-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d6c2a52a9664a9c1657e5a95b3a40c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2e36ff23f511c7746fc3df8d57d8123 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28d508f4d8a6c528283eeed26cf65eb7 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2012-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98c6ee4532356ae996689a7d2eab9087 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8170d150534776b5e66e53fda3446e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e490c54b3c73923f984ad3ca50466ba3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a56f0656c5f7249ff0c4557f25b53648 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c059b8d5142358c70d08d2f7b2ff797c |
| publicationDate | 2015-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102965429-B |
| titleOfInvention | Application of microRNA-320(miR-320a) and its antisense nucleotide in diagnosis, prevention and treatment of cardiovascular diseases |
| abstract | The invention discloses application of miR-320a and its antisense nucleotide respectively in risk assessment/diagnosis of atherosclerotic cardiovascular and cerebrovascular diseases and prevention and treatment of atherosclerotic cardiovascular and cerebrovascular diseases. The inventor conducts a lot of experimental study to prove that: the miR-320a level changes (rises) in blood plasma (or serum) of high-risk groups of atherosclerotic cardiovascular and cerebrovascular diseases (atherosclerosis, coronary heart disease, myocardial infarction and stroke) and coronary heart disease, and the miR-320a level rise can induce atherosclerosis, inflammatory state and blood-lipid metabolic disorder obviously; and miR-320a's antisense nucleotide anti-miR-320a can alleviate, prevent and treat the atherosclerotic cardiovascular and cerebrovascular diseases and relevant disorder states. According to the invention, finally conclusions are obtained as the following: (1) miR-320a can be taken as a novel target for drugs, the nucleotide anti-miR-320a can be used for preventing and treating atherosclerotic cardiovascular and cerebrovascular diseases (such as atherosclerosis, coronary heart disease, myocardial infarction and stroke and the like); and (2) the peripheral blood miR-320a level can be adopted as a new biomarker, and its expression level can be detected for predicting and assessing the risk of atherosclerotic cardiovascular diseases or assisting in diagnosing already existing atherosclerotic cardiovascular diseases. Also, the fluorescent quantitative PCR (polymerase chain) technology can be employed to detect the expression level of miR-320a in patient peripheral blood so as to assist diagnosis of the atherosclerotic cardiovascular diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105349666-A |
| priorityDate | 2012-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 97.